Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response

Infection and Immunity

Volumn 80, Issue 6, 2012, Pages 2026-2034

  Brudecki, Laura ^a   Ferguson, Donald A ^a   McCall, Charles E ^b   Gazzar, Mohamed El ^a  

^a East Tennessee State University   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; CD11B ANTIGEN; CD31 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL GROWTH; BIOACCUMULATION; BONE MARROW CELL; CECUM; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; EX VIVO STUDY; HEMATOPOIETIC STEM CELL; IMMUNE RESPONSE; MACROPHAGE; MALE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PERITONITIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SUPPRESSOR CELL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TH1 CELL; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; CELL DIFFERENTIATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; GERMFREE ANIMAL; IMMUNOLOGY; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD11B; ARGINASE; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; MYELOID CELLS; NITRIC OXIDE; SEPSIS; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 85047689277     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00239-12     Document Type: Article

References (43)

1. Almand B, et al. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166:678-689.
2. Belikoff B, Hatfield S, Sitkovsky M, Remick DG. 2011. Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice. Shock 35:382-387.
3. Belikoff BG, et al. 2011. A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J. Immunol. 186:2444 -2453.
4. Bone RC, et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644 -1655.
5. Bronte V. 2009. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur. J. Immunol. 39:2670 -2672.
6. Bronte V, et al. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170:270 -278.
7. Brudecki L, et al. 5 December 2011. Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis. Infect. Immun. doi:10.1128/IAI. 05480-11.
8. Condamine T, Gabrilovich DI. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32:19 -25.
9. Cuenca AG, et al. 2011. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 17:281-292.
10. Delano MJ, et al. 2007. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204:1463-1474.
11. Ellaban E, Bolgos G, Remick D. 2004. Selective macrophage suppression during sepsis. Cell Immunol. 231:103-111.
12. Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S. 2010. Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE catabolism in myeloid cells. J. Leukoc. Biol. 88:839-848.
13. Gabrilovich DI, Nagaraj S. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174.
14. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. 2001. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166:5398 -5406.
15. Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:138 -150.
16. Huang X, et al. 2009. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl. Acad. Sci. U. S. A. 106:6303- 6308.
17. Inoue S, et al. 2010. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol. 184:1401-1409.
18. Kung JT, Brooks SB, Jakway JP, Leonard LL, Talmage DW. 1977. Suppression of in vitro cytotoxic response by macrophages due to induced arginase. J. Exp. Med. 146:665- 672.
19. Kusmartsev S, et al. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63:4441- 4449.
20. Kusmartsev S, Gabrilovich DI. 2003. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 74: 186-196.
21. Kusmartsev S, et al. 2008. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14:8270-8278.
22. Lederer JA, Rodrick ML, Mannick JA. 1999. The effects of injury on the adaptive immune response. Shock 11:153-159.
23. Ling V, et al. 1997. Structural identification of the hematopoietic progenitor antigen ER-MP12 as the vascular endothelial adhesion molecule PECAM-1 (CD31). Eur. J. Immunol. 27:509 -514.
24. Mazuski JE, et al. 2002. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg. Infect. (Larchmt.) 3:161-173.
25. Merlino JI, Yowler CJ, Malangoni MA. 2004. Nosocomial infections adversely affect the outcomes of patients with serious intraabdominal infections. Surg. Infect. (Larchmt.) 5:21-27.
26. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. 2000. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164:6166-6173.
27. Munder M, Eichmann K, Modolell M. 1998. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+T cells correlates with Th1/Th2 phenotype. J. Immunol. 160:5347-5354.
28. Oberholzer A, Oberholzer C, Moldawer LL. 2001. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16:83-96.
29. Ostrand-Rosenberg S, Sinha P. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182:4499-4506.
30. Osuchowski MF, Welch K, Siddiqui J, Remick DG. 2006. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177:1967-1974.
31. Osuchowski MF, Welch K, Yang H, Siddiqui J, Remick DG. 2007. Chronic sepsis mortality characterized by an individualized inflammatory response. J. Immunol. 179:623- 630.
32. Peranzoni E, et al. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22:238 -244.
33. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463- 467.
34. Remick DG, et al. 2001. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit. Care Med. 29:473- 481.
35. Rittirsch D, Flierl MA, Ward PA. 2008. Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 8:776 -787.
36. Rodriguez S, et al. 2009. Dysfunctional expansion of hematopoietic stem cells and block of myeloid differentiation in lethal sepsis. Blood 114:4064- 4076.
37. Sander LE, et al. 2010. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 207:1453-1464.
38. Shubin NJ, Monaghan SF, Ayala A. 2011. Anti-inflammatory mechanisms of sepsis. Contrib. Microbiol. 17:108 -124.
39. Vuk-Pavlovic S, et al. 2010. Immunosuppressive CD14+HLA-DRlow/monocytes in prostate cancer. Prostate 70:443- 455.
40. Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A. 2005. Leukocyte apoptosis and its significance in sepsis and shock. J. Leukoc. Biol. 78:325-337.
41. Wysocka M, et al. 2001. IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J. Immunol. 166:7504 -7513.
42. Xia S, et al. 2011. Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. J. Biol. Chem. 286:23591-23599.
43. Yang L, et al. 2008. Abrogation of TGF-beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23-35.